Beau Ances on amyloid biomarkers in Alzheimer...

What will Alzheimer’s disease diagnosis look like in 5–10 years? In this episode of In Conversation With…, Laura Hart is joined by the authors behind The Lancet Neurology Series on Future Directions in Alzheimer’s Disease and Related Disorders: Clifford Jack (Mayo Clinic), Charlo ...  Show more

For decades, a diagnosis of vanishing white matter disease came with no real treatment — so how is an old blood-pressure pill offering hope? In this episode of In Conversation With…The Lancet Neurology, Deputy Editor Laura Hart speaks with Professor Marjo van der Knaap (Amsterdam ...  Show more

Dr. Rae Bacharach discusses the Neurology Today article, "Individuals Can Now Request a Blood Test for Alzheimer disease - Why Some Dementia Experts Are Wary". Show references: https://journals.lww.com/neurotodayonline/fulltext/2023/10190/individuals_can_now_request_a_blood_test_ ...  Show more

In this interview, dementia expert Gil D. Rabinovici, MD, discusses monoclonal antibodies that target beta-amyloid–-including a recent phase 3 trial of donanemab published in JAMA-–and reviews considerations for their use in patients with Alzheimer disease.

<stron ...

What are Biomarkers? And why are they useful in Alzheimer's Disease Research. 

Dr. Manisha Bahl interviews Dr. Jeffrey Prescott. Diffuse Tensor MRI Structural Connectivity and PET Amyloid Burden in Preclinical Autosomal Dominant Alzheimer Disease: The DIAN Cohort. Prescott et al. Radiology 2022; 302:143–150.